SlideServe
Menu
Préférences
© SlideServe · v2026

Restrictive Lung Diseases

kristin-elpida avatar
45 diapositives · 1.1K Views · Nov 15, 2014

Restrictive Lung Diseases. Dr. Raid Jastania. “Don’t forget the homework”. Restrictive Lung Diseases. Definition: Reduced lung compliance More pressure needed to expand lungs Lungs are stiff Pulmonary function test: Low VEV1, Low FVC (the ratio FEV1/FVC is normal).

Restrictive Lung Diseases - slide 1
01 / 45Restrictive Lung Diseases
1 / 17

Télécharger la présentation

Restrictive Lung Diseases
Une image / un lien ci-dessous est fourni (tel quel) pour télécharger la présentation

Politique de téléchargement : le contenu du site vous est fourni TEL QUEL pour votre information et votre usage personnel ; il ne peut être vendu, concédé sous licence ni partagé sur d’autres sites sans l’accord de son auteur.Le contenu vous est fourni TEL QUEL, pour votre information et votre usage personnel uniquement. Téléchargez la présentation en cliquant sur ce lien. Lors du téléchargement, si vous ne parvenez pas à télécharger une présentation, l’éditeur a peut-être supprimé le fichier de son serveur.Pendant le téléchargement, si vous ne parvenez pas à obtenir une présentation, le fichier a peut-être été supprimé par l’éditeur.

F I N

Plus de contenu associé

Transcription de la présentation
  1. Restrictive Lung Diseases Dr. Raid Jastania

  2. “Don’t forget the homework”

  3. Restrictive Lung Diseases • Definition: • Reduced lung compliance • More pressure needed to expand lungs • Lungs are stiff • Pulmonary function test: Low VEV1, Low FVC (the ratio FEV1/FVC is normal)

  4. Restrictive Lung Diseases • Types: • Chest wall abnormality (not primary lung) • Deformities, kyphoscoliosis • Neuromuscular disease • Primary lung disease • Acute: Acute Respiratory Distress Syndrome ARDS • Chronic: • Occupational: Asbestosis, silicosis, coal worker pneumoconiosis • Interstitial lung disease (interstitial pneumonia), Idiopathic pulmonary fibrosis • Immune diseases: Sarcoidosis, SLE, RA, Wegener • Physical injury: : Radiation • Drugs: Chemotherapy, methotrexate

  5. Restrictive Lung Diseases • Gas exchange barrier: • Basement membrane • Interstitial tissue • Endothelial cell • Epithelial cell

  6. Restrictive Lung Diseases • Initial injury to cells: endothelial, epithelial • This is followed by reaction that end by interstitial fibrosis – stiff lung – dyspnea • Damage to epithelium and vessels – abnormal ventilation-perfusion – Hypoxia – cyanosis • Pulmonary hypertension – cor pulmonale

  7. Acute Lung Injury – Acute Respiratory Distress Syndrome ARDS

  8. Acute Lung Injury – Acute Respiratory Distress Syndrome ARDS • Continuum of the same condition • Characterized by progressive respiratory failure: • Acute onset dyspnea • Decreased arterial oxygen pressure (hypxemia) • Bilateral pulmonary infiltrates (edema) • Absence of evidence of left-sided heart failure • Most common cause of non-cardiogenic pulmonary edema

  9. Acute Lung Injury – Acute Respiratory Distress Syndrome ARDS • Can be caused by many conditions: • Direct injury to lung: Pneumonia, aspiration, pulmonary contusion (trauma), fat embolism, near-drowning, inhalation injury, post-lung transplant • Indirect Lung injury: Sepsis, severe trauma with shock, cadiopulmonary bypass, acute pancreatitis, transfusion, uremia

  10. Acute Lung Injury – Acute Respiratory Distress Syndrome ARDS • Pathogenesis: • Epithelial or endothelial injury • Inflammation: increased vascular permeability, edema, fluid in alveoli, loss of diffusion capacity, loss of surfactant, damage of typeII pneumocytes • Proinflammatory cytokines>> Anti-inflammatory cytokines • Cytokines: • IL-8: Chemotaxis of neutrophils • IL-1, TNF • Neutrophils: • Oxidative damage • Attract other inflmmatory cells: IL-1, TNF • Fibrosis/Repair: TGF-alpha, PDGF

  11. Acute Lung Injury – Acute Respiratory Distress Syndrome ARDS • Morphology: • Diffuse alveolar damage • 1. Exudative phase • 2. Proliferative phase • 3. Fibrotic phase

  12. Acute Lung Injury – Acute Respiratory Distress Syndrome ARDS • 1. Exudative phase • Lung is dark, red, firm • 0-7 days • Capillary congestion • Necrosis of epithelial cells • Interstitial, alveolar edema, hemorrhage • Collection of neutrophils • Alveolar collapse (loss of surfactant) • Fibrin thrombi • Hyaline membrane lining alveolar ducts

  13. Acute Lung Injury – Acute Respiratory Distress Syndrome ARDS • 2. Proliferative phase • 1-3 weeks • Proliferation of type II pneumocytes • Macrophages, removing cell debris • 3. Fibrotic phase • Resolution with minimal fibrosis • Repair/Fibrosis, thick alveolar walls • Progressive fibrosis (honeycomb lung) Rare

  14. Acute Lung Injury – Acute Respiratory Distress Syndrome ARDS • Clinical: • Mortality was 100% • Now 30-40% with good ICU support • Poor prognosis: old age, multisystem failure, high levels of IL-1

  15. Chronic Restrictive Lung Diseases

  16. Chronic Restrictive Lung Diseases • Group of different diseases • Similar clinical, pulmonary function test and pathological findings • Represent 15% of non-infectious diseases of lungs • End-stage: diffuse interstitial pulmonary fibrosis (Honeycomb lung)

  17. Restrictive Lung Diseases • Primary lung disease • Acute: Acute Respiratory Distress Syndrome ARDS • Chronic: • Occupational: Asbestosis, silicosis, coal worker pneumoconiosis • Interstitial lung disease (interstitial pneumonia), Idiopathic pulmonary fibrosis • Immune diseases: Sarcoidosis, SLE, RA, Wegener • Physical injury: : Radiation • Drugs: Chemotherapy, methotrexate

  18. Idiopathic Pulmonary Fibrosis • Cryptogenic fibrosing alveolitis • Unknown etiology • Diffuse interstitial fibrosis • Sever hypoxemia, and cyanosis • Male>Female, 60y • Diagnosis of exclusion

  19. Idiopathic Pulmonary Fibrosis • Pathogenesis: • Alveolar wall injury • Alveolitis: inflammation, edema • Neutrophil, macrophages, lymphocytes • Interstitial Fibrosis • ? Immune disorder: association with immune diseases: RA, SLE, Sjogren…. • Macrophages: IL-8, FGF, TGF-beta, PDGF

  20. Idiopathic Pulmonary Fibrosis • Morphology: • Interstitial lung disease • Interstitial pneumonia • Usual interstitial pneumonia • Non-specific interstitial pneumonia • Desquamative interstitial pneumonia • Lymophocytic interstitial pneumonia • Bronchiolitis Obliterance Organizing Pneumonia BOOP

  21. Idiopathic Pulmonary Fibrosis • Morphology: • Usual interstitial Pneumonia UIP • Random pattern of interstitial chronic inflammation, fibrosis, in variable stages • 80% idiopathic, 20% associated with collagen vascular diseases

  22. Idiopathic Pulmonary Fibrosis • Clinical: • Gradual, non-productive cough • Progressive Dyspnea, cyanosis • Finger clubbing • Mean survival 2-4 years

  23. Sarcoidosis • Multisystem disease • Unknown etiology • Non-caseating granuloma in many tissues and organs • Diagnosis of exclusion

  24. Sarcoidosis • Presenting Picture: • Bilateral hilar lymphadenopathy • Lung involvement, lung nodules • Other organs: skin, eye, any tissue • Adult, younger than <40y • Common in US blacks • Higher in non-smokers

  25. Sarcoidosis • Pathogenesis • Unknown cause • Immunologic factors • Activated CD4 T cells • Increase number of CD4 Tcells • High level f IL-2, Interferon-gamma, IL-8, TNF • Genetic factors: • Familial, racial clustering • Association with HLA-A1, HLA-B8 • Environmental factors • ? Viral infection, mycobacteria

  26. Sarcoidosis • Morphology: • Non-caseating granuloma • Collection of epithelioid histiocytes rimmed by CD4 T-cells and fibroblasts • Giant cells • Schqumann bodies (calcium and protein_ • Asteroid bodies (inclusions)

  27. Sarcoidosis • Hilar and paratracheal lymph nodes 75-90% • Lung involvement in 90% • Diffuse interstitial fibrosis 5-15% • Sking 25% • Erythema nodosum: raised, tender, nodule on anterior aspect of legs • Eye, Lacrimal glands • Iritis, loss of vision • Choroiditis, retinitis • Parotid gland 10%, Spleen 75%, Liver, Bone marrow, any organ

  28. Sarcoidosis • Clinical: • Asymptomatic in many • Lymphadenopathy, skin, eye lesion • Respiratory disease: dyspnea, dry cough • Fever, fatigue, wt. Loss • Unpredictable course • Progressive or relapsing remitting disease • 10% develop progressive fibrosis

  29. Hypersensitivity Pneumonitis • Immune mediated disease • Type III and type IV hypersensitivity • Inflammatory disease • Affect alveoli (mainly) (Allergic Alveolitis) • Occupational disease • Restrictive disease

  30. Hypersensitivity Pneumonitis • Presentation: • Acute: 4-6 hours following exposure, Fever, cough , dyspnea • Chronic: cough, dyspnea, wt. Loss

  31. Hypersensitivity Pneumonitis • Causes • Fungal/Bacterial • Farmer lung: micropolyspora • Humidifier lung: Actinomycetes • Cheese washer’s lung: Penicillium • Animal Product • Pigeon breeder’s lung • Chemicals

  32. Hypersensitivity Pneumonitis • Morphology: • Particles: not usually seen • Inflammation, edema, Peribronchial • Lymphocytes, plasma cells • Non-caseating granuloma • Fibrosis

  33. Collagen Vascular Disease • Associated with interstitial Pneumonia • Similar to Idiopathic Pulmonary Fibrosis

  34. Wegener Granulomatosis • Necrotizing vasculitis • Affect both upper and lower respiratory tract • Parenchymal necrotizing granuloma • URT: sinusitis, epistaxis, nasal perforation • LRT: cough, hemoptysis, chest pain